Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Cardiovasc Diabetol. 2024 Jul 18;23(1):257. doi: 10.1186/s12933-024-02348-2.
BACKGROUND: Diabetes mellitus (DM) and Lp(a) are well-established predictors of coronary artery disease (CAD) outcomes. However, their combined association remains poorly understood. OBJECTIVE: To investigate the relationship between elevated Lp(a) and DM with CAD outcomes. METHODS: Retrospective analysis of the MGB Lp(a) Registry involving patients ≥ 18 years who underwent Lp(a) measurements between 2000 and 2019. Exclusion criteria were severe kidney dysfunction, malignant neoplasms, and prior atherosclerotic cardiovascular disease (ASCVD). The primary outcome was a combination of cardiovascular death or myocardial infarction (MI). Elevated Lp(a) was defined as > 90th percentile (≥ 216 nmol/L). RESULTS: Among 6,238 patients who met the eligibility criteria, the median age was 54, 45% were women, and 12% had DM. Patients with DM were older, more frequently male, and had a higher prevalence of additional cardiovascular risk factors. Over a median follow-up of 12.9 years, patients with either DM or elevated Lp(a) experienced higher rates of the primary outcome. Notably, those with elevated Lp(a) had a higher incidence of the primary outcome regardless of their DM status. The annual event rates were as follows: No-DM and Lp(a) < 90th% - 0.6%; No-DM and Lp(a) > 90th% - 1.3%; DM and Lp(a) < 90th% - 1.9%; DM and Lp(a) > 90th% - 4.7% (p < 0.001). After adjusting for confounders, elevated Lp(a) remained independently associated with the primary outcome among both patients with DM (HR = 2.66 [95%CI: 1.55-4.58], p < 0.001) and those without DM (HR = 2.01 [95%CI: 1.48-2.74], p < 0.001). CONCLUSIONS: Elevated Lp(a) constitutes an independent and incremental risk factor for CAD outcomes in patients with and without DM.
背景:糖尿病(DM)和脂蛋白(a)(Lp(a))是冠心病(CAD)结局的既定预测因素。然而,它们的联合相关性仍知之甚少。
目的:探讨升高的 Lp(a)与 DM 与 CAD 结局的关系。
方法:对 MGB Lp(a) 注册研究进行回顾性分析,该研究纳入了 2000 年至 2019 年期间接受 Lp(a)测量的年龄≥18 岁的患者。排除标准为严重肾功能不全、恶性肿瘤和既往动脉粥样硬化性心血管疾病(ASCVD)。主要结局是心血管死亡或心肌梗死(MI)的组合。升高的 Lp(a)定义为>第 90 百分位数(≥216nmol/L)。
结果:在符合入选标准的 6238 名患者中,中位年龄为 54 岁,45%为女性,12%患有 DM。患有 DM 的患者年龄更大,更常为男性,且存在更多的心血管危险因素。在中位随访 12.9 年后,无论 DM 状态如何,患有 DM 或升高的 Lp(a)的患者发生主要结局的比率更高。值得注意的是,无论 DM 状态如何,升高的 Lp(a)患者发生主要结局的发生率更高。每年的事件发生率如下:无 DM 和 Lp(a)<第 90 百分位数-0.6%;无 DM 和 Lp(a)>第 90 百分位数-1.3%;DM 和 Lp(a)<第 90 百分位数-1.9%;DM 和 Lp(a)>第 90 百分位数-4.7%(p<0.001)。在调整混杂因素后,升高的 Lp(a)在患有 DM 的患者(HR=2.66[95%CI:1.55-4.58],p<0.001)和无 DM 的患者(HR=2.01[95%CI:1.48-2.74],p<0.001)中与主要结局独立相关。
结论:升高的 Lp(a)是伴有或不伴有 DM 的 CAD 结局的独立且递增的危险因素。
Eur J Prev Cardiol. 2024-5-11
Cardiovasc Diabetol. 2020-3-19
Am Heart J Plus. 2025-7-21
Curr Cardiol Rep. 2025-6-25
Lipids Health Dis. 2025-5-24
Diabetes Metab Syndr Obes. 2025-5-17
Am J Prev Cardiol. 2024-12-15
J Am Coll Cardiol. 2024-4-23